Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer

23 Aug 2022

Abstract excerpt

BACKGROUND: Colorectal cancer (CRC), the most common cancer type, causes high morbidity and mortality. Patients who develop drug resistance to oxaliplatin-based regimens have short overall survival. Thus, identifying molecules involved in the development of oxaliplatin resistance is critical for designing therapeutic strategies. METHODS: A proteomic screen was performed to reveal altered protein kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Microtubule and mitosis dynamics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35999268
DOI: 10.1038/s41416-022-01946-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancerPMID 35999268Read ↗

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell LinesSemantic proximity Read ↗

Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancerSemantic proximity Read ↗

Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancerSemantic proximity Read ↗

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cellsSemantic proximity Read ↗

Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal CancerSemantic proximity Read ↗

HIPK2 Cooperates with KRAS Signaling and Associates with Colorectal Cancer Progression.Semantic proximity Read ↗

In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancerSemantic proximity Read ↗

USP10/XAB2/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancerSemantic proximity Read ↗

FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expressionSemantic proximity Read ↗

Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repairSemantic proximity Read ↗

The Chk2 protein kinase.Semantic proximity Read ↗

PBK/TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTENSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.